About
OptimaCure provides personalized treatment for patients with cancer by repositioning failed cancer drugs. The companys solution employs multiple robust screening approaches that indicate the most appropriate and optimal drug combinations for treating individual cancer patients. The companys process identifies the patients most likely to respond positively to the suggested drug treatment. It can also identify broader applications for the repositioned cancer drugs in treating additional indications. By combining multiple technologies (e.g. in vivo, in vitro, and in silico), OptimaCures proprietary approach enhances the understanding of the mode of action of the selected failed drugs and their combination and repositions them toward the appropriate cancer patients. OptimaCure is a subsidiary of Goldman Hirsh Partners.
Q&A
- What is OptimaCure's primary focus?
- OptimaCure focuses on providing personalized cancer treatment by repositioning failed cancer drugs, identifying optimal drug combinations for individual patients.
- When was OptimaCure founded?
- OptimaCure was founded in August 2013.
- What is OptimaCure's current operational status?
- OptimaCure is currently inactive, having ceased operations in January 2019.
- Where is OptimaCure headquartered?
- OptimaCure's headquarters are located in Herzliya, Israel.
- What is OptimaCure's employee count?
- OptimaCure has an employee count in the 1-10 range.
- What is OptimaCure's relationship with Goldman Hirsh Partners?
- OptimaCure is a subsidiary of Goldman Hirsh Partners.
- What is OptimaCure's primary sector classification?
- OptimaCure's primary sector is Health Tech & Life Sciences.
Sectors & technology
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | optimacure.com/ |
|---|
Identifiers & details
| Founded | 2013-8 |
|---|---|
| Employees (exact) | 6 |
| Status reason | Non Active, Jan 2019 ceased to operate |